Newsy's Latest Health News

The FDA has approved Adu Helm, the first Alzheimer's drug in nearly 20 years, developed by Biogen. Despite its approval, there are concerns about its effectiveness and high cost of $56,000 annually. Meanwhile, a survey reveals that 78% of vaccine-hesitant Americans are unlikely to change their stance, even as 64% of adults have received at least one COVID-19 vaccine dose.

What new insight or understanding did you gain from this video?